1153 related articles for article (PubMed ID: 27043774)
1. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
McMurray JJ; Krum H; Abraham WT; Dickstein K; Køber LV; Desai AS; Solomon SD; Greenlaw N; Ali MA; Chiang Y; Shao Q; Tarnesby G; Massie BM;
N Engl J Med; 2016 Apr; 374(16):1521-32. PubMed ID: 27043774
[TBL] [Abstract][Full Text] [Related]
2. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
[TBL] [Abstract][Full Text] [Related]
3. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.
Kristensen SL; Mogensen UM; Tarnesby G; Gimpelewicz CR; Ali MA; Shao Q; Chiang Y; Jhund PS; Abraham WT; Dickstein K; McMurray JJV; Køber L
Eur J Heart Fail; 2018 Jan; 20(1):136-147. PubMed ID: 28948656
[TBL] [Abstract][Full Text] [Related]
5. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren, Enalapril, or Both in Heart Failure.
Silva AR; Martini A; Neves FA
N Engl J Med; 2016 Aug; 375(7):701-2. PubMed ID: 27532844
[No Abstract] [Full Text] [Related]
9. Aliskiren, Enalapril, or Both in Heart Failure.
McMurray JJ; Dickstein K; Køber LV
N Engl J Med; 2016 Aug; 375(7):702. PubMed ID: 27532843
[No Abstract] [Full Text] [Related]
10. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
[TBL] [Abstract][Full Text] [Related]
11. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.
Sidik NP; Solomon SD; Latini R; Maggioni AP; Wright M; Gimpelewicz CR; Pitt B; McMurray JJ
Cardiovasc Drugs Ther; 2011 Aug; 25(4):315-21. PubMed ID: 21779784
[TBL] [Abstract][Full Text] [Related]
12. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL
Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717
[TBL] [Abstract][Full Text] [Related]
13. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics.
Krum H; McMurray JJ; Abraham WT; Dickstein K; Køber L; Desai AS; Solomon SD; Chiang Y; Gimpelewicz C; Reimund B; Ali MA; Tarnesby G; Massie BM;
Eur J Heart Fail; 2015 Oct; 17(10):1075-83. PubMed ID: 26511146
[TBL] [Abstract][Full Text] [Related]
14. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ
Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
[TBL] [Abstract][Full Text] [Related]
16. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
Gilbert CJ; Gomes T; Mamdani MM; Hellings C; Yao Z; Garg AX; Wald R; Harel Z; Juurlink DN
Can J Cardiol; 2013 May; 29(5):586-91. PubMed ID: 23541666
[TBL] [Abstract][Full Text] [Related]
17. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
18. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.
Solomon SD; Shin SH; Shah A; Skali H; Desai A; Kober L; Maggioni AP; Rouleau JL; Kelly RY; Hester A; McMurray JJ; Pfeffer MA;
Eur Heart J; 2011 May; 32(10):1227-34. PubMed ID: 21317148
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
[TBL] [Abstract][Full Text] [Related]
20. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Anker SD; Negassa A; Coats AJ; Afzal R; Poole-Wilson PA; Cohn JN; Yusuf S
Lancet; 2003 Mar; 361(9363):1077-83. PubMed ID: 12672310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
